Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAN 2021 | Targeting CGRP for migraine prevention: the story so far

It is now well evidenced that calcitonin gene-related peptide (CGRP) receptor signaling plays a key role in migraine pathophysiology. Dimos-Dimitrios Mitsikostas, MD, PhD, National & Kapodistrian University of Athens, Athens, Greece, gives an overview of the CGRP story so far in preventive migraine treatment. Prior to the develop of agents targeted against the CGRP pathway, all available treatments for patients with migraine were repurposed agents. When the causal role of CGRP was established, agents targeting CGRP ligands were tested in clinical trials, but failed due to safety. Anti-CGRP monoclonal antibodies were then developed which were found to be efficient in the prevention of episodic and chronic migraine, while avoiding many of the side effects of earlier agents. Representing the first migraine-specific agents available, these therapeutics have achieved exciting results in clinical trials to date. This interview took place during the European Academy of Neurology 2021 congress.


Prof. Mitsikostas reports the following disclosures:
Research and traveling grants, honoraria and consultation fees from Allergan, Amgen, Biogen, Cefaly, Eli Lily, ElectroCore, Genesis Pharma, Lundbeck, Novartis, Merz, Sanofi, and Teva.
Trials for Cefaly, Eli Lily, ElectroCore, Lundbeck, Novartis, Merz, Sanofi, and Teva.
Associate Editor in the Journal of Headache and Pain.
Co-chair of the Management group of the Headache Scientific Panel at the European Academy of Neurology and President of the Hellenic Headache Society.